| [1] |
Rymer JA, Jones WS. Femoropopliteal in-stent restenosis[J]. Circ Cardiovasc Interv, 2018, 11(12): e007559.
|
| [2] |
Zhao LP, Xu WT, Wang L, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up[J]. Coron Artery Dis, 2015, 26(1): 5-10.
|
| [3] |
Conte MS, Pomposelli FB, Clair DG, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication[J]. J Vasc Surg, 2015, 61(3 Suppl): 2S-41S.
|
| [4] |
Zheng H, Calligaro KD, Jang J, et al. Duplex ultrasound for diagnosis of failing stents placed for lower extremity arterial occlusive disease[J]. Ann Vasc Surg, 2019. [Epub ahead of print]
|
| [5] |
Garcia-Guimaraes M, Antuña P, Maruri-Sanchez R, et al. Calcified neoatherosclerosis causing in-stent restenosis: prevalence, predictors, and implications[J]. Coron Artery Dis, 2019, 30(1): 1-8.
|
| [6] |
Luo H, Zhou C, Chi J, et al. The role of tauroursodeoxycholic acid on dedifferentiation of vascular smooth muscle cells by modulation of endoplasmic reticulum stress and as an oral drug inhibiting in-stent restenosis[J]. Cardiovasc Drugs Ther, 2019, 33(1): 25-33.
|
| [7] |
Kim W, Choi D. Treatment of femoropopliteal artery in-stent restenosis[J]. Korean Circ J, 2018, 48(3): 191-197.
|
| [8] |
Elmahdy MF, Buonamici P, Trapani M, et al. Long-term primary patency rate after nitinol self-expandable stents implantation in long, totally occluded femoropopliteal (TASC Ⅱ C & D) lesions[J]. Heart Lung Circ, 2017, 26(6): 604-611.
|
| [9] |
Wang J, Jin X, Huang Y, et al. Endovascular stent-induced alterations in host artery mechanical environments and their roles in stent restenosis and late thrombosis[J]. Regen Biomater, 2018, 5(3): 177-187.
|
| [10] |
Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting[J]. J Am Coll Cardiol, 2012, 59(1): 16-23.
|
| [11] |
Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study[J]. Circulation, 2013, 127(23): 2307-2315.
|
| [12] |
Iftikhar O, Oliveros K, Tafur AJ, et al. Prevention of femoropopliteal in-stent restenosis with cilostazol: A Meta-analysis[J]. Angiology, 2016, 67(6): 549-555.
|
| [13] |
Kinstner CM, Lammer J, Willfort-Ehringer A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial[J]. JACC Cardiovasc Interv, 2016, 9(13): 1386-1392.
|
| [14] |
Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience[J]. Radiology, 2008, 248(1): 297-302.
|
| [15] |
Shin SH, Baril DT, Chaer RA, et al. Cryoplasty offers no advantage over standard balloon angioplasty for the treatment of in-stent stenosis[J]. Vascular, 2013, 21(6): 349-354.
|
| [16] |
Bague N, Julia P, Sauguet A, et al. Femoropopliteal in-stent restenosis repair: midterm outcomes after paclitaxel eluting balloon use (PLAISIR Trial)[J]. Eur J Vasc Endovasc Surg, 2017, 53(1): 106-113.
|
| [17] |
Grotti S, Liistro F, Angioli P, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study[J]. J Endovasc Ther, 2016, 23(1): 52-57.
|
| [18] |
Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study[J]. J Endovasc Ther, 2014, 21(1): 1-8.
|
| [19] |
Krankenberg H, Tubler T, Ingwersen M, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR) trial[J]. Circulation, 2015, 132(23): 2230-2236.
|
| [20] |
Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease[J]. Circ Res, 2015, 116(9): 1599-1613.
|
| [21] |
Tomoi Y, Soga Y, Iida O, et al. Impact of drug-eluting stent implantation for femoropopliteal in-stent occlusion[J]. J Endovasc Ther, 2016, 23(3): 461-467.
|
| [22] |
Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies[J]. J Am Coll Cardiol, 2013, 61(24): 2417-2427.
|
| [23] |
Bosiers M, Deloose K, Callaert J, et al. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial[J]. J Endovasc Ther, 2015, 22(1): 1-10.
|
| [24] |
Gorgani F, Telis A, Narakathu N, et al. Long-term outcomes of the Viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery[J]. J Invasive Cardiol, 2013, 25(12): 670-674.
|
| [25] |
Werner M. Bioresorbable scaffolds for the SFA: new developments[J]. J Cardiovasc Surg (Torino), 2014, 55(4): 455-459.
|
| [26] |
Shammas NW, Shammas GA, Aasen N, et al. Number of blades-up runs using jetstream XC atherectomy for optimal tissue debulking in patients with femoropopliteal artery in-stent restenosis[J]. J Vasc Interv Radiol, 2015, 26(12): 1847-1851.
|
| [27] |
Schmidt A, Zeller T, Sievert H, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study[J]. J Endovasc Ther, 2014, 21(1): 52-60.
|
| [28] |
Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)[J]. JACC Cardiovasc Interv, 2015, 8(1 Pt A): 92-101.
|
| [29] |
Armstrong EJ, Thiruvoipati T, Tanganyika K, et al. Laser atherectomy for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther, 2015, 22(4): 506-513.
|
| [30] |
Shammas NW, Shammas GA, Jerin M. Differences in patient selection and outcomes between SilverHawk atherectomy and laser ablation in the treatment of femoropopliteal in-stent restenosis: A retrospective analysis from a single center[J]. J Endovasc Ther, 2013, 20(6): 844-852.
|
| [31] |
Brodmann M, Rief P, Froehlich H, et al. Neointimal hyperplasia after silverhawk atherectomy versus percutaneous transluminal angioplasty (PTA) in femoropopliteal stent reobstructions: A controlled, randomized pilot trial[J]. Cardiovasc Intervent Radiol, 2013, 36(1): 69-74.
|
| [32] |
Beschorner U, Krankenberg H, Scheinert D, et al. Rotational and aspiration atherectomy for infrainguinal in-stent restenosis[J]. Vasa, 2013, 42(2): 127-133.
|
| [33] |
van den Berg JC, Pedrotti M, Canevascini R, et al. In-stent restenosis: mid-term results of debulking using excimer laser and drug-eluting balloons: sustained benefit?[J]. J Invasive Cardiol, 2014, 26(7): 333-337.
|
| [34] |
Kokkinidis DG, Hossain P, Jawaid O, et al. Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1-year outcomes for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther, 2018, 25(1): 81-88.
|
| [35] |
Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries[J]. J Vasc Surg, 2013, 58(3): 682-686.
|
| [36] |
Milnerowicz A, Milnerowicz A, Kuliczkowski W, et al. Rotational atherectomy plus drug-coated balloon angioplasty for the treatment of total in-stent occlusions in iliac and infrainguinal arteries[J]. J Endovasc Ther, 2019, 26(3): 316-321.
|
| [37] |
Nolan BW, De Martino RR, Stone DH, et al. Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass[J]. J Vasc Surg, 2011, 54(3): 730-735.
|
| [38] |
Bradbury AW, Adam DJ, Bell J, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received[J]. J Vasc Surg, 2010, 51(5 Suppl): 18S-31S.
|